📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-04 17:38
631 analysed today
631
Today
134,273
All-time analysed
40,194
Positive
6,287
Negative
79,947
Neutral
7,777
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
81 announcements match the current filters (relevance ≥ 5).
Lupin Secures US FDA Approval for Modafinil Tablets (US Market Size $70.7M)
Lupin Limited has received US FDA approval for its Abbreviated New Drug Application (ANDA) for Modafinil Tablets USP in 100 mg and 200 mg strengths. The drug is bioequivalent to Nuvo Pharmaceuticals' Provigil Tablets and is indicated to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder. According to IQVIA MAT July 2026 data, Modafinil Tablets had estimated annual sales of USD 70.7 million in the US. This expands Lupin's US formulations portfolio against its TTM revenue base of Rs 27,958 Cr.
Confidence: HIGH
What changedLupin has received final US FDA approval to market generic Modafinil Tablets in 100 mg and 200 mg strengths in the United States.
Why it mattersProvides an incremental generic revenue stream in the US market, expanding Lupin's central nervous system / sleep disorder portfolio.
US Market Size (MAT Jul 2026): USD 70.7 millionDosage Strengths: 100 mg and 200 mgLupin TTM Revenue Context: Rs 27,958 Cr
📅 Short termSupports positive sentiment around US FDA pipeline clearance, with revenue realization expected post-commercial launch.
📈 Long termIncremental generic contribution; overall impact is modest relative to Lupin's overall annual revenue scale.
⚠ Risk flags
- US generic price erosion
- Competitive intensity among existing generic suppliers
Key Highlights
Received US FDA ANDA approval for Modafinil Tablets USP (100 mg and 200 mg).
Approved as bioequivalent to reference listed drug Provigil Tablets.
Addressable US market size estimated at USD 70.7 million per IQVIA MAT Jul 2026.
👀 What to Watch
Track the commercial launch timeline and generic market share ramp-up in upcoming quarterly disclosures.
Lupin Subsidiary Signs Exclusive European Licensing Deal for YUVEZZI Worth Up to €75M
Lupin's wholly owned subsidiary, VISUfarma B.V., has entered into an exclusive licensing agreement with Visus Therapeutics, Inc. to commercialize YUVEZZI (an FDA-approved presbyopia eye drop) across the European Union, UK, Switzerland, Norway, and Iceland. The total potential consideration is up to €75 million through to first commercial sales, consisting of a €20 million strategic investment via a SAFE instrument and up to €55 million in regulatory and commercial milestones, plus royalties. The agreement grants exclusive commercialization and marketing rights for an initial 20-year term post-launch per country.
Confidence: HIGH
What changedLupin's subsidiary VISUfarma acquired exclusive European licensing and commercialization rights for presbyopia treatment drug YUVEZZI from Visus Therapeutics.
Why it mattersExpands Lupin's specialty ophthalmology portfolio in Europe with an FDA-approved differentiated therapy, supporting its high-margin specialty care growth strategy.
Total potential milestone consideration: up to €75 millionStrategic investment component (SAFE): €20 millionMilestone payments component: up to €55 millionInitial license term: 20 years post-launch
📅 Short termSentiment positive on specialty pipeline expansion; immediate cash outflow is limited to the €20 million SAFE investment.
📈 Long termEnhances long-term specialty revenue streams in Europe once regulatory clearances and commercial distribution scale over the 20-year license period.
⚠ Risk flags
- Regulatory approval delays across various European health authorities
- Commercial adoption risks for novel presbyopia eye treatments
Key Highlights
Exclusive commercialization rights for YUVEZZI in the EU, UK, Switzerland, Norway, and Iceland
Total consideration up to €75 million prior to first commercial sales (€20M equity investment + up to €55M milestones)
Initial agreement term of 20 years from the date of first commercial sale in each country
Product is already US FDA-approved; UK Marketing Authorisation Application (MMA) submitted via MHRA
👀 What to Watch
Track the timeline of regulatory approvals across European health authorities (including UK MHRA review) and subsequent product rollout dates.
Lupin Receives US FDA Final Approval for Pitolisant Tablets (4.45 mg & 17.8 mg)
Lupin Limited has received final approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets in 4.45 mg and 17.8 mg strengths. The product is bioequivalent to Wakix® and expands the company's US central nervous system and oral solid generic portfolio. This approval adds to Lupin's US product basket, backing its overall business base with TTM revenue of ₹27,958 Cr.
Confidence: HIGH
What changedLupin received final regulatory approval from the U.S. FDA for generic Pitolisant Tablets (4.45 mg and 17.8 mg).
Why it mattersEnables Lupin to launch a generic alternative to Wakix® in the US market, contributing incremental revenue to its formulation business against a TTM revenue base of ₹27,958 Cr.
Dosage strengths approved: 4.45 mg and 17.8 mgAnnouncement date: August 17, 2026Lupin TTM Revenue: ₹27,958 Cr
📅 Short termPositive sentiment for US formulation portfolio; investors will watch for commercial rollout and initial distribution ramp-up.
📈 Long termIncremental addition to Lupin's differentiated generic pipeline, supporting long-term US revenue stability subject to generic competitive intensity.
⚠ Risk flags
- US generic price erosion
- Potential competition from other generic filers
Key Highlights
Final U.S. FDA approval received for Pitolisant Tablets in 4.45 mg and 17.8 mg strengths
Determined as bioequivalent to reference listed drug Wakix®
Approval announced on August 17, 2026 for commercialization in the US market
👀 What to Watch
Track the commercial launch timeline, market share capture post-launch, and competitive dynamics/pricing for generic Pitolisant in the US.
₹8,277 Cr Revenue: Lupin Reports Record Q1 FY27 with 25% EBITDA Margin Guidance
Lupin delivered a record Q1 FY27 with revenue of ₹8,277 cr, up 32% YoY, and EBITDA of ₹2,464 cr. The US business performed strongly at $366 million, though management expects full-year US sales to moderate to the $1.1B-$1.2B range due to new competition in Mirabegron and Tolvaptan. India business grew 13.9% YoY, led by a 31.8% surge in the Diabetes segment. Management maintained its FY27 guidance of high single-digit revenue growth and EBITDA margins of approximately 25%.
Confidence: HIGH
What changedLupin transitioned from a period of recovery to record-high quarterly revenues and margins, while providing a clear roadmap for complex generic launches in the US.
Why it mattersThe record performance and 25% margin guidance signal improved operational leverage and a successful shift toward high-margin chronic and complex generic segments.
Q1 Revenue: ₹8,277 crQ1 Revenue vs TTM Revenue: 29.6%US Sales Guidance (FY27): $1.1B - $1.2BEBITDA Margin Guidance: 25%India Sales Force: 11,300R&D Spend (% of sales): 7.4%
📅 Short termThe stock may react positively to the record earnings and margin expansion, though management's cautious outlook on US competition for the rest of the year may cap gains.
📈 Long termStructural growth is expected from the doubling of complex products in the US and a target to reach 70% chronic share in India over 5 years.
⚠ Risk flags
- Increased competitive intensity in key US products (Mirabegron, Tolvaptan)
- Ongoing remediation at Pithampur Unit II
- US generic price erosion
Key Highlights
Achieved record quarterly revenue of ₹8,277 cr, marking the 16th consecutive quarter of YoY growth.
US business recorded $366 million in sales for Q1, with a full-year guidance set at $1.1B to $1.2B.
India formulation business grew 13.9% YoY, with the Chronic segment now accounting for 67% of the portfolio.
R&D investment maintained at 7.4% of sales, focusing on a pipeline of 50+ US products over the next 3 years.
Received EIRs with VAI status for Ankleshwar and Somerset facilities, improving regulatory compliance standing.
👀 What to Watch
Watch for the impact of competitive pricing on US margins in Q2 and Q3, and monitor the launch timeline of Semaglutide variants in India during H2 FY27.
USD 568m Market Opportunity: Lupin Receives US FDA Approval for Hyperkalemia Generic
Lupin has received US FDA approval for Sodium Zirconium Cyclosilicate for Oral Suspension, a generic version of AstraZeneca’s Lokelma®. The product is indicated for treating hyperkalemia and addresses a US market valued at approximately USD 568 million (IQVIA MAT June 2026). This approval strengthens Lupin's position as the 3rd largest pharmaceutical player in the US by prescriptions. While actual revenue will depend on market share capture, the target market size represents roughly 17% of Lupin's TTM revenue.
Confidence: HIGH
What changedLupin has secured regulatory clearance to market a generic version of the high-value drug Lokelma® in the United States.
Why it mattersThis approval adds a significant molecule to Lupin's US portfolio, supporting its strategy to grow through complex generics and offset price erosion in commoditized segments.
Target Market Size (US): USD 568 millionMarket Size vs TTM Revenue: ~17%TTM Revenue: ₹27,958 CrTTM PAT: ₹5,356 CrOperating Profit Margin: 31.5%
📅 Short termThe approval is likely to be viewed positively by the market as it demonstrates R&D execution and adds to the US product pipeline.
📈 Long termConsistent approvals in the USD 500m+ market category are essential for Lupin to maintain its 24% expected growth rate and expand its US generic footprint.
⚠ Risk flags
- Generic price erosion
- Competition from other generic manufacturers
- US payer consolidation
Key Highlights
Received US FDA approval for Sodium Zirconium Cyclosilicate for Oral Suspension (5g and 10g packets).
Targeting a US market with estimated annual sales of USD 568 million as of June 2026.
Product is bioequivalent to the reference drug Lokelma® by AstraZeneca Pharmaceuticals LP.
Lupin currently maintains a 3.4% share in the Indian Pharmaceutical Market and is 3rd in US prescriptions.
Company reported a strong TTM OPM of 31.5% and PAT of ₹5,356 Cr as of FY26.
👀 What to Watch
Investors should monitor the commercial launch timeline and the number of competing generic entrants, which will determine Lupin's pricing power and market share in this molecule.
33% YoY Revenue Growth in Q1 FY27; EBITDA Margins Expand to 30%
Lupin reported a strong Q1 FY27 with consolidated revenue growing 33% YoY to ₹8,217.2 cr, significantly driven by a 43% surge in North American sales. EBITDA increased 50% YoY to ₹2,463.5 cr, reflecting a margin expansion to 30.0% from 26.6% in the previous year. The India business grew 14% YoY to ₹2,379.6 cr, outperforming the market in chronic segments like Anti-Diabetes. Net income rose 16% YoY to ₹1,415 cr, supported by robust growth in EMEA (65%) and LATAM (71%) regions.
Confidence: HIGH
What changedLupin has delivered a significant quarterly beat in revenue and margins, driven by volume growth in the US and chronic therapy leadership in India.
Why it mattersThe margin expansion to 30% indicates improved operating leverage and a successful shift toward complex generics and specialty products, which are less prone to commoditized price erosion.
Q1 FY27 Revenue: ₹8,217.2 crRevenue vs TTM Revenue: 29.4%EBITDA Margin: 30.0%YoY EBITDA Growth: 50%US Sales Growth: 43%
📅 Short termThe stock is likely to react positively to the margin expansion and strong US performance, which exceeded historical averages.
📈 Long termStructural focus on complex generics, biosimilars, and emerging therapies (targeting 65%+ share of new product launches by FY31) positions the company for sustained margin improvement.
⚠ Risk flags
- Regulatory risk at Pithampur Unit II (OAI status)
- US generic price erosion in commoditized molecules
- Payer consolidation in the US market
Key Highlights
North America sales grew 43% YoY to ₹3,590.8 cr, now contributing 42% of total revenue.
EBITDA margins expanded by 340 bps YoY to reach 30.0% in Q1 FY27.
India Anti-Diabetes segment grew 31.8% YoY, nearly double the IPM growth of 17.3%.
EMEA region recorded 65% YoY growth, reaching ₹1,034.4 cr following strategic expansions.
Company maintains a strong pipeline with plans to launch 20+ products in India and 15+ in the US during FY27.
👀 What to Watch
Monitor the remediation progress at Pithampur Unit II, which remains under OAI status, and the execution of the 15+ planned ANDA filings in the US to sustain growth momentum.
Lupin Q1 FY27: 33% YoY Revenue Growth to ₹8,217 Cr; EBITDA Margins Expand to 30%
Lupin reported a robust Q1 FY27 with consolidated sales reaching ₹8,217.2 Cr, a 33% YoY increase. EBITDA grew significantly by 50% YoY to ₹2,463.5 Cr, with margins expanding to 30.0% from 23.2% in the prior year. Growth was primarily driven by the North American market, which surged 43% YoY to ₹3,590.8 Cr, and a steady 14% growth in the India business. Regulatory progress was noted with EIRs received for Ankleshwar and Somerset facilities, though Pithampur Unit II remains under remediation.
Confidence: HIGH
What changedLupin has achieved a significant step-up in quarterly revenue and operating margins, supported by regulatory clearances for two key manufacturing sites.
Why it mattersThe margin expansion to 30% indicates successful transition toward complex generics and specialty products, reducing reliance on commoditized generics and improving overall cash flow profile.
Q1 FY27 Sales: ₹8,217.2 CrEBITDA Margin: 30.0%US Sales Growth (YoY): 43%Net Income: ₹1,415.0 CrQ1 Sales vs TTM Revenue: 29.4%
📅 Short termThe stock is likely to react positively to the strong margin beat and robust growth in the US and India markets.
📈 Long termStructural focus on complex generics (inhalations/injectables) and biosimilars, combined with cost optimization, positions the company for sustained double-digit growth.
⚠ Risk flags
- US generic price erosion (mid-single digit)
- OAI status at Pithampur Unit II
- High payer concentration in the US market
Key Highlights
Consolidated sales grew 33% YoY to ₹8,217.2 Cr, representing ~29% of TTM revenue.
EBITDA margin expanded by 680 bps YoY to 30.0%, driven by operating leverage and complex product mix.
North America sales increased 43% YoY to ₹3,590.8 Cr, now contributing 42% of total revenue.
India business grew 13.9% YoY to ₹2,379.6 Cr, outperforming the Indian Pharmaceutical Market (IPM) growth of 13.5%.
Received EIR with VAI status for Ankleshwar and Somerset facilities; Pithampur Unit II remediation is ongoing.
👀 What to Watch
Investors should monitor the execution of 15+ planned US product launches and 20+ India launches in FY27, alongside the regulatory resolution timeline for the Pithampur Unit II facility.
33.3% Sales Growth in Q1 FY27: Lupin Reports ₹1,417 Cr PAT and 31.4% EBITDA Margin
Lupin reported a strong start to FY27 with consolidated sales growing 33.3% YoY to ₹8,217.2 Cr. EBITDA margins expanded by 210 bps YoY to 31.4%, primarily driven by a 42.9% surge in U.S. sales (₹3,434.8 Cr) and 13.9% growth in the India market. While PAT grew 16% YoY to ₹1,417 Cr, it saw a slight sequential (QoQ) decline from ₹1,468.7 Cr. The company has transitioned to a net cash position with a net debt-to-equity ratio of -0.12.
Confidence: HIGH
What changedLupin has significantly strengthened its balance sheet to a net cash position and achieved a substantial scale-up in its U.S. and Emerging Market segments.
Why it mattersThe results demonstrate successful execution in complex generics and high-margin markets, moving the company toward its 24% expected growth trajectory with improved operating leverage.
Q1 Sales: ₹8,217.2 CrYoY Sales Growth: 33.3%EBITDA Margin: 31.4%Net Debt: ₹-2,830.8 CrU.S. Sales Growth: 42.9%R&D Spend: ₹607.7 Cr
📅 Short termThe strong YoY growth in top-line and EBITDA is likely to be viewed positively by the market, although the sequential dip in PAT and margins may lead to some consolidation.
📈 Long termStructural improvements in the U.S. product mix and a debt-free balance sheet position Lupin well for sustained R&D-led growth in complex generics and biosimilars.
⚠ Risk flags
- Sequential EBITDA margin compression of 410 bps
- High tax expense growth (up 209.5% YoY)
- U.S. generic price erosion risks
Key Highlights
Consolidated sales reached ₹8,217.2 Cr, up 33.3% YoY and 11.2% QoQ.
U.S. sales grew 42.9% YoY to ₹3,434.8 Cr, now accounting for 42% of global revenue.
EBITDA increased 42.8% YoY to ₹2,579.9 Cr, though margins compressed 410 bps sequentially from Q4 FY26.
Net Debt stands at negative ₹2,830.8 Cr, indicating a strong net cash balance.
R&D investment for the quarter was ₹607.7 Cr, representing 7.4% of sales.
👀 What to Watch
Watch for the sustainability of U.S. margins and the execution of the 21 exclusive First-to-File (FTF) opportunities. Investors should also monitor if the sequential margin compression (from 35.5% to 31.4%) is a one-off due to product mix or a trend.
₹7,171.9 Cr Standalone Revenue: Lupin Reports 25.6% YoY Growth in Q1 FY27
Lupin Limited reported a strong start to FY27 with standalone revenue from operations reaching ₹7,171.9 cr, a 25.6% increase compared to ₹5,708.6 cr in Q1 FY26. Standalone Net Profit grew 27.6% YoY to ₹2,714.6 cr, supported by improved operational performance. The quarter also saw the integration of several European entities (VISUfarma) effective April 1, 2026, and a subsidiary settled an antitrust dispute for ₹265.41 cr (USD 30 million) in April 2026. Standalone EPS rose to ₹59.37 from ₹46.60 in the year-ago period.
Confidence: HIGH
What changedLupin has reported its first quarter results for FY27, showing significant standalone growth and the formal inclusion of new European subsidiaries in its corporate structure.
Why it mattersThe results demonstrate strong growth momentum in the core standalone business and progress in the company's strategy to expand its European footprint through acquisitions.
Standalone Revenue (Q1 FY27): ₹7,171.9 crStandalone Net Profit (Q1 FY27): ₹2,714.6 crYoY Revenue Growth (Standalone): 25.6%Antitrust Settlement Value: ₹2,654.1 millionESOP Allotment: 53,425 shares
📅 Short termThe stock may react positively to the strong YoY growth in standalone revenue and profit, reflecting healthy operational performance.
📈 Long termLupin's structural growth is tied to its expansion into underpenetrated European markets and its shift toward complex generics and biosimilars, which are expected to drive margin expansion.
⚠ Risk flags
- Ongoing antitrust litigation risks
- US generic price erosion
- Integration risks of new European subsidiaries
Key Highlights
Standalone revenue from operations increased 25.6% YoY to ₹7,171.9 cr.
Standalone Net Profit after tax rose to ₹2,714.6 cr, up from ₹2,128.1 cr in Q1 FY26.
Basic Standalone EPS improved to ₹59.37 compared to ₹46.60 in the previous year's quarter.
A wholly owned subsidiary settled an ongoing antitrust dispute for ₹265.41 cr (USD 30 million) in April 2026.
Allotted 53,425 equity shares under ESOP, increasing paid-up capital by ₹0.1 million.
👀 What to Watch
Investors should monitor the consolidated financial performance to assess the margin impact of the newly integrated European VISUfarma entities. Key focus remains on the execution of the complex generics pipeline in the US and any further developments in the 'In Re Generic Pharmaceuticals Antitrust Litigation'.
$77.9M Market Opportunity: Lupin Receives US FDA Approval for Diazepam Injection
Lupin has received US FDA approval for its Abbreviated New Drug Application (ANDA) for Diazepam Injection USP (10 mg/2 mL), a generic version of Valium®. The product is indicated for managing anxiety disorders and represents an addressable market of approximately USD 77.9 million (~Rs 650 Cr) in the U.S. as of May 2026. This approval strengthens Lupin's position in the complex injectables segment, which is a key part of its margin expansion strategy.
Confidence: HIGH
What changedLupin has secured regulatory clearance to market a generic version of Diazepam in a prefilled syringe format in the United States.
Why it mattersThis adds a new revenue stream in the high-margin complex injectables category, helping offset potential price erosion in the company's commoditized oral solids portfolio.
Estimated Annual US Sales: USD 77.9 millionMarket Size vs TTM Revenue: ~2.3%TTM Revenue: Rs 27958 CrProduct Strength: 10 mg/2 mL (5 mg/mL)
📅 Short termThe approval is likely to be viewed positively by the market as it demonstrates continued execution of the U.S. generic pipeline.
📈 Long termConsistent approvals in the injectables and biosimilars space are structural drivers for Lupin's goal of 24% expected growth and margin expansion.
⚠ Risk flags
- US generic price erosion
- Competition from other generic entrants
- USFDA regulatory compliance at other manufacturing sites
Key Highlights
Received US FDA approval for Diazepam Injection USP, 10 mg/2 mL (5 mg/mL) Single-Dose Prefilled Syringes.
Target market size estimated at USD 77.9 million in annual U.S. sales per IQVIA MAT May 2026 data.
Product is bioequivalent to the reference listed drug Valium® Injection by Hoffman-LaRoche, Inc.
Lupin is currently the 3rd largest pharmaceutical player in the U.S. by prescriptions.
👀 What to Watch
Investors should monitor the commercial launch timeline and Lupin's ability to capture market share in the U.S. injectables space. The contribution of this product to the U.S. revenue (currently 42% from inhalations) will be key to sustaining the 31.5% OPM.
Lupin Launches Sugammadex Injection in the U.S. Following FDA Approval
Lupin has received U.S. FDA approval and announced the immediate launch of Sugammadex Injection (200 mg/2 mL and 500 mg/5 mL) in the United States. The product is a bioequivalent version of Merck's Bridion®, used for reversing neuromuscular blockade in surgical patients aged 2 and older. This launch strengthens Lupin's complex generic and injectable portfolio, which is a key driver for its U.S. business where it currently ranks as the 3rd largest player by prescriptions. Given Lupin's TTM revenue of ₹27,958 Cr, high-value injectable launches are critical for maintaining its 31.5% operating profit margin.
Confidence: HIGH
What changedLupin has received final regulatory clearance and commenced the commercial sale of Sugammadex Injection in the U.S. market.
Why it mattersThis launch adds a high-value injectable to Lupin's U.S. portfolio, supporting its strategy to move away from commoditized generics toward complex formulations with higher entry barriers and better margins.
Product Strengths: 200 mg/2 mL and 500 mg/5 mLTTM Revenue: ₹27,958 CrU.S. Market Rank: 3rd largest by prescriptionsOperating Profit Margin (TTM): 31.5%
📅 Short termThe immediate launch is expected to provide a marginal boost to U.S. generic sales and sentiment in the coming weeks.
📈 Long termConsistent launches in the complex generic space are vital for Lupin to sustain its 24% expected growth rate and improve ROCE, which currently stands at 27%.
⚠ Risk flags
- Generic price erosion in the U.S. market
- Competition from other generic manufacturers for the same molecule
- Consolidation of U.S. payers
Key Highlights
Launched Sugammadex Injection in two strengths: 200 mg/2 mL and 500 mg/5 mL single-dose vials.
Product is bioequivalent to Merck’s Bridion® Injection, targeting the surgical reversal market.
Approved for use in both adult and pediatric patients aged 2 years and older.
Lupin maintains a strong U.S. presence as the 3rd largest pharmaceutical player by prescriptions.
Aligns with the company's strategy to focus on complex generics and injectables for margin expansion.
👀 What to Watch
Investors should monitor the U.S. revenue growth in the upcoming quarters to gauge the market share capture of this molecule. Additionally, watch for any further approvals in the complex injectable pipeline which are intended to offset generic price erosion.
82.2% Stake in Kaveri Therapeutics via $1.6M Oncology Program Spin-out
Lupin's US subsidiary has spun out two oncology programs, LNP7457 (PRMT5) and LNP8701 (SOS1), into a newly formed clinical-stage entity, Kaveri Therapeutics. In exchange for granting exclusive perpetual licenses valued at USD 1.6 million, Lupin has acquired an 82.2% equity stake (332,000 shares) in Kaveri. This strategic move allows Lupin to advance these therapies for solid tumors through a specialized vehicle that will raise independent capital for global clinical trials. While the immediate financial impact is small relative to Lupin's Rs 27,958 Cr TTM revenue, it optimizes R&D spending while retaining significant ownership.
Confidence: HIGH
What changedLupin has transitioned two early-stage oncology assets into a majority-owned independent subsidiary to facilitate specialized development and external funding.
Why it mattersThis allows Lupin to offload the high costs of global clinical trials to a separate entity while maintaining a majority stake in the potential upside of high-value oncology therapies.
Equity Stake Acquired: 82.2%Consideration Value: USD 1.6 millionShares Acquired: 332,000 Common SharesDeal Value vs TTM Revenue: ~0.05%Target Net Worth: NIL
📅 Short termNeutral; the transaction is small in financial terms and will not impact immediate earnings, though it reflects a proactive R&D strategy.
📈 Long termStrategic; if the oncology programs succeed in clinical trials, Kaveri could become a high-value asset or a candidate for a future IPO/exit, benefiting Lupin's valuation.
⚠ Risk flags
- Clinical trial failure risk for early-stage oncology programs
- Execution risk for a newly incorporated entity
- Potential dilution of Lupin's stake as Kaveri raises external capital
Key Highlights
Acquired 82.2% equity stake in Kaveri Therapeutics, Inc. U.S.A. via a licensing agreement
Licensing of two oncology programs (PRMT5 and SOS1) valued at USD 1.6 million
Kaveri was incorporated on May 20, 2026, and currently has NIL turnover and net worth
Lupin Inc. will provide seed funding and Kaveri will seek additional external capital for clinical trials
Programs reported positive data at ASCO meetings in 2025 and 2026
👀 What to Watch
Monitor Kaveri's ability to raise external capital and the clinical trial progression of the PRMT5 and SOS1 programs, as these are the primary drivers of value for this new subsidiary.
₹18 Dividend Declared; Lupin Schedules 44th AGM for August 4, 2026
Lupin Limited has issued a notice for its 44th Annual General Meeting (AGM) scheduled for August 4, 2026, where it will seek shareholder approval for a final dividend of ₹18 per equity share (900% of face value). The company's Integrated Report for FY 2025-26 highlights significant R&D progress, including the filing of Ranibizumab in the U.S. and Denosumab in Japan. Additionally, Lupin has entered a strategic collaboration with TB Alliance for the commercialization of Telacebec across 140 countries. The board has also proposed the appointment of Deloitte Haskins & Sells as statutory auditors for a five-year term.
Confidence: HIGH
What changedThe company has formalized the dividend payout and provided a comprehensive update on its transition toward complex generics and biosimilars through its FY26 Integrated Report.
Why it mattersThe ₹18 dividend represents a steady payout relative to the TTM EPS of ₹116.74. The progress in biosimilars and NCEs is critical for maintaining the 31.5% OPM and offsetting generic price erosion in the U.S. market.
Final Dividend: ₹18 per shareDividend as % of Face Value: 900%Cost Auditor Remuneration (FY27): ₹10,00,000AGM Date: August 04, 2026Cut-off date for e-voting: July 28, 2026
📅 Short termThe stock may see neutral to positive movement as investors react to the dividend confirmation and the detailed R&D pipeline updates provided in the integrated report.
📈 Long termStructural growth is tied to the successful commercialization of the biosimilar pipeline and expansion into European markets (Italy/Spain), which are expected to drive margin expansion over the next 2-3 years.
⚠ Risk flags
- US generic price erosion
- USFDA warning letters at Tarapur and Mandideep facilities
- Consolidation of payers in the US generics market
Key Highlights
Final dividend of ₹18 per equity share of face value ₹2 recommended for FY 2025-26.
Strategic collaboration with TB Alliance for Telacebec (Q203) to supply over 140 countries.
Successful primary endpoints met for biosimilars of Aflibercept, Denosumab, Nivolumab, and Pegfilgrastim.
Proposed appointment of Deloitte Haskins & Sells as Statutory Auditors for a 5-year term starting from the 44th AGM.
Low Global Warming Potential (GWP) inhalers identified to reduce Scope-3 emissions by approximately 35%.
👀 What to Watch
Investors should note the record date/cut-off date of July 28, 2026, for dividend eligibility and e-voting. Key focus should remain on the execution timeline for the U.S. Ranibizumab launch and the integration of the Nanomi B.V. acquisition expected by December 2025.
₹18 Dividend: Lupin Sets July 17, 2026, as Record Date for 900% Final Payout
Lupin Limited has finalized July 17, 2026, as the record date for its final dividend of ₹18 per equity share (900% of face value). This dividend was previously recommended by the Board on May 07, 2026, and is now subject to shareholder approval at the upcoming 44th AGM on August 04, 2026. Based on the TTM EPS of ₹116.74, the payout ratio stands at approximately 15.4%. The company maintains a strong financial position with a low debt-to-equity ratio of 0.04 and TTM PAT of ₹5,356 Cr.
Confidence: HIGH
What changedThe company has officially scheduled its 44th AGM and fixed the record date for the ₹18 per share final dividend recommended earlier in May.
Why it mattersThe dividend confirms the company's commitment to shareholder returns, supported by a strong ROCE of 27% and significant margin expansion seen in recent quarters (OPM at 31.5%).
Dividend per share: ₹18Dividend % of Face Value: 900%Record Date: July 17, 2026Estimated Payout vs TTM PAT: ~15.4%TTM EPS: ₹116.74
📅 Short termThe stock price is expected to adjust downwards by the dividend amount on the ex-dividend date (typically one business day prior to the record date).
📈 Long termLimited; this is a routine annual dividend distribution consistent with the company's profitability profile.
Key Highlights
Final dividend of ₹18 per equity share of face value ₹2 (900%) recommended for FY 2025-26.
Record date for determining dividend entitlement fixed as Friday, July 17, 2026.
44th Annual General Meeting (AGM) scheduled for Tuesday, August 04, 2026.
Estimated total dividend payout represents approximately 15.4% of TTM PAT of ₹5,356 Cr.
Dividend to be paid within 30 days of declaration at the AGM.
👀 What to Watch
Investors seeking the dividend must hold the shares in their demat account by the record date of July 17, 2026. Watch for management commentary during the August 4 AGM regarding the Nanomi B.V. acquisition and USFDA facility status.
₹18 Dividend: Lupin Sets July 17 as Record Date for 900% Final Dividend
Lupin Limited has announced the record date for its final dividend of ₹18 per equity share (900% of face value) for FY 2025-26. The record date is fixed for July 17, 2026, with the 44th Annual General Meeting (AGM) scheduled for August 04, 2026. Based on the current market price of ₹2517, the dividend yield stands at approximately 0.71%. The payout is well-supported by the company's TTM EPS of ₹116.74, representing a payout ratio of roughly 15.4%.
Confidence: HIGH
What changedThe company has finalized the administrative timeline (Record Date and AGM date) for the dividend distribution previously recommended by the Board in May 2026.
Why it mattersThis confirms the cash outflow to shareholders and provides a platform (the AGM) for management to discuss the company's 24% expected growth rate and complex generic pipeline.
Dividend per share: ₹18Dividend as % of Face Value: 900%Record Date: July 17, 2026Dividend Yield: ~0.71%TTM EPS: ₹116.74
📅 Short termThe stock may experience minor price adjustments around the ex-dividend date as the ₹18 per share value is factored out of the price.
📈 Long termLimited structural impact as this is a routine annual dividend; however, the low payout ratio (15.4%) suggests the company is retaining significant capital for its planned ₹700-800 Cr annual capex.
Key Highlights
Final dividend of ₹18 per equity share of ₹2 each recommended for the financial year ended March 31, 2026.
Record date for determining dividend entitlement is fixed as Friday, July 17, 2026.
44th Annual General Meeting to be held on Tuesday, August 04, 2026, via video conferencing.
Dividend payment will be processed within 30 days of shareholder approval at the AGM.
The dividend represents a 900% payout on the face value of the company's equity shares.
👀 What to Watch
Investors seeking the dividend must hold the shares before the ex-dividend date (typically one business day prior to the July 17 record date). Watch the upcoming AGM for management updates on the Nanomi B.V. acquisition and USFDA facility statuses.
Lupin Receives US FDA EIR with VAI Classification for Somerset Facility
Lupin has received the Establishment Inspection Report (EIR) from the U.S. FDA for its manufacturing facility in Somerset, New Jersey. The inspection, conducted from April 13 to April 17, 2026, resulted in a Voluntary Action Indicated (VAI) classification. This is a positive regulatory outcome, indicating that the facility meets acceptable compliance standards, which is crucial for Lupin as the 3rd largest pharmaceutical player in the U.S. by prescriptions. With TTM revenue of ₹27,958 Cr, maintaining compliant U.S. facilities is essential for sustaining its core export business.
Confidence: HIGH
What changedThe U.S. FDA has concluded its review of the Somerset facility inspection, granting it a VAI status, which effectively clears the site for continued operations and new approvals.
Why it mattersRegulatory compliance in the U.S. is critical for Lupin's margins, especially since niche categories like inhalations contribute 42% of U.S. revenue. A VAI status avoids the restrictive 'Official Action Indicated' (OAI) status that can halt new product launches.
Inspection Start Date: April 13, 2026Inspection End Date: April 17, 2026TTM Revenue: ₹27,958 CrMarket Cap: ₹1,09,919 CrU.S. Market Rank: 3rd largest by prescriptions
📅 Short termThe announcement removes regulatory uncertainty regarding the Somerset facility, likely providing a neutral-to-positive sentiment boost in the coming weeks.
📈 Long termEnsures the Somerset facility remains a viable part of Lupin's global supply chain, supporting its long-term strategy in complex generics and biosimilars.
⚠ Risk flags
- US generic price erosion
- Regulatory risks at other facilities (Tarapur and Mandideep)
- Payer consolidation in the US market
Key Highlights
Inspection conducted at the Somerset, New Jersey facility from April 13 to April 17, 2026
Received Voluntary Action Indicated (VAI) classification from the U.S. FDA
Lupin maintains a strong U.S. presence as the 3rd largest player by prescriptions
Company operates 15 manufacturing sites and 7 research centers globally
TTM revenue stands at ₹27,958 Cr with an OPM of 31.5%
👀 What to Watch
Investors should monitor for any new product approvals (ANDAs) linked to the Somerset facility, as the VAI status clears the path for future U.S. launches from this site.
Lupin Increases Stake in Philippines Subsidiary MPPI to 99.89% via Nanomi B.V.
Lupin Limited has successfully consolidated its ownership in Multicare Pharmaceuticals Philippines, Inc. (MPPI), increasing its stake from 56.28% to 99.89%. This was achieved through the acquisition of 11,794,497 shares by Lupin's wholly-owned Dutch subsidiary, Nanomi B.V., alongside a buyback of 61,118 shares by MPPI. The transaction, effective July 01, 2026, simplifies the corporate structure and gives Lupin near-total control over its Philippines operations. A minor buyback of 30,559 shares remains in progress to complete the transition.
Confidence: HIGH
What changedLupin transitioned from a majority owner to a near-100% owner of its Philippines-based subsidiary, MPPI, through its Dutch arm Nanomi B.V.
Why it mattersThis move eliminates minority interest leakage, allowing nearly 100% of MPPI's profits to accrue to Lupin's shareholders and providing full operational control in a key emerging market.
Stake Increase: 56.28% to 99.89%Shares Acquired: 11,794,497Shares Bought Back: 61,118Pending Buyback: 30,559TTM Revenue: Rs 27,958 Cr
📅 Short termThe news confirms the execution of previously announced plans and is likely to be viewed neutrally to slightly positively by the market as it streamlines the corporate structure.
📈 Long termStrategically positive as it strengthens Lupin's footprint in Southeast Asia and simplifies global governance, though the financial impact depends on the standalone scale of the Philippines business.
⚠ Risk flags
- Acquisition cost for the minority stake was not disclosed in this filing
Key Highlights
Effective shareholding in MPPI increased from 56.28% to 99.89% as of July 01, 2026.
Wholly-owned subsidiary Nanomi B.V. completed the acquisition of 11,794,497 shares from existing minority holders.
MPPI completed a buyback of 61,118 shares from two shareholders, with 30,559 shares still pending.
The consolidation follows earlier definitive agreements announced in April and May 2026.
Lupin maintains a strong financial position with TTM PAT of Rs 5,356 Cr to support such consolidations.
👀 What to Watch
Investors should monitor upcoming quarterly results for the full consolidation of MPPI's earnings and management commentary regarding growth targets in the Philippines market.
EMA Approves Lupin's NaMuscla Expansion for Pediatric Use with New Strengths
Lupin has received European Medicines Agency (EMA) approval to expand the indication of NaMuscla to include pediatric patients (ages 6-17) for the treatment of non-dystrophic myotonic disorders (NDM). The approval introduces two new dosage strengths, 62 mg and 83 mg, supplementing the existing 167 mg capsule. NaMuscla remains the only approved treatment for NDM symptoms in Europe, a rare condition with a prevalence of 1 in 100,000. This regulatory milestone supports Lupin's specialty portfolio growth in Europe, following its recent €190 million (approx. ₹2,000 Cr) expansion into Italy and Spain.
Confidence: HIGH
What changedLupin's NaMuscla, previously approved only for adults in Europe, now has marketing authorization for pediatric and adolescent patients with new lower-dose strengths.
Why it mattersThis strengthens Lupin's specialty drug pipeline in Europe, a key growth pillar intended to offset US generic price erosion. While the patient population is small (rare disease), specialty products typically command better pricing and margins than commoditized generics.
New Dosage Strengths: 62 mg and 83 mgDisease Prevalence: 1:100,000Recent EU Expansion Investment: €190 millionTTM Revenue: ₹27,958 CrOperating Profit Margin: 31.5%
📅 Short termThe news is sentimentally positive for the stock as it demonstrates progress in the high-margin specialty segment, though immediate revenue impact will be gradual due to reimbursement timelines.
📈 Long termSupports Lupin's structural shift toward complex generics and specialty medicines, which is critical for maintaining its 27% ROCE and 31.5% OPM in the face of global pricing pressures.
⚠ Risk flags
- Limited addressable market due to rare disease status
- National reimbursement hurdles in individual EU countries
- Execution risk in European market expansion
Key Highlights
EMA approval extends NaMuscla usage to children (6-11 years, min 20 kg) and adolescents (12-17 years).
Introduces two new dosage strengths of 62 mg and 83 mg to the existing 167 mg portfolio.
Targets Non-Dystrophic Myotonias (NDM), a rare disease with a prevalence of 1:100,000.
NaMuscla is currently the only licensed antimyotonic agent for this indication in Europe.
Approval follows the Pediatric Investigation Plan (PIP) requirements for European marketing.
👀 What to Watch
Watch for the timeline of national reimbursement and access processes across European markets, which will determine the actual revenue ramp-up for these new indications.
Lupin Receives Tentative U.S. FDA Approval for Enzalutamide Tablets (40mg to 160mg)
Lupin has received tentative approval from the U.S. FDA for its Abbreviated New Drug Application for Enzalutamide Tablets in 40 mg, 80 mg, 120 mg, and 160 mg strengths. The 40 mg and 80 mg versions are bioequivalent to the reference drug Xtandi by Astellas, which is used in oncology. Lupin is also introducing 120 mg and 160 mg strengths to provide alternative dosing options for healthcare providers. This approval strengthens Lupin's specialty pipeline in the U.S. market, although a commercial launch will depend on final approval and patent timelines.
Key Highlights
Received tentative U.S. FDA approval for Enzalutamide Tablets in four strengths: 40 mg, 80 mg, 120 mg, and 160 mg.
The 40 mg and 80 mg strengths are bioequivalent to the reference listed drug (RLD) Xtandi Tablets of Astellas.
Lupin is offering unique 120 mg and 160 mg strengths to provide alternative dosing options for patients.
The product targets the oncology segment, expanding Lupin's complex generic portfolio in the United States.
👀 What to Watch
Investors should view this as a positive development for Lupin's U.S. pipeline, though they should monitor the timeline for final approval and patent expiry of the innovator drug for actual revenue impact.
Lupin Launches Azilsartan Medoxomil in US with 180-Day First-to-File Exclusivity
Lupin Limited has launched Azilsartan Medoxomil Tablets (40mg and 80mg) in the United States following US FDA approval. The company holds exclusive first-to-file status for this product, making it eligible for 180 days of generic drug exclusivity. The tablets are a generic version of Edarbi®, used for treating hypertension, and address a market valued at approximately USD 53.5 million in annual sales as of April 2026.
Key Highlights
Launched Azilsartan Medoxomil Tablets in 40mg and 80mg strengths in the U.S. market.
Granted exclusive first-to-file status with 180-day generic drug exclusivity.
Targets the U.S. hypertension market which has estimated annual sales of USD 53.5 million.
The product is a bioequivalent generic version of Azurity Pharmaceuticals' Edarbi®.
👀 What to Watch
Investors should monitor the revenue contribution from this launch over the next two quarters, as the 180-day exclusivity period typically yields higher margins before other generic competitors enter.
